FDA Inspection 1299118 — Lilly S.A.
The FDA completed an inspection of Lilly S.A. on February 14, 2024 in Alcobendas. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 14, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Alcobendas (Spain)
Additional Details
Mutual Recognition Agreement (MRA)